CC BY-NC-ND 4.0 · Laryngorhinootologie 2021; 100(S 02): S99-S100
DOI: 10.1055/s-0041-1727890
Abstracts
Head-Neck-Oncology

TRIM24 as a prognostic biomarker for survival and local recurrence in HNSCC

C Idel
1   UKSH - Campus Lübeck, Hals-, Nasen- und Ohrenheilkunde, Lübeck
,
L Klapper
2   UKSH - Campus Lübeck, Institut für Pathologie, Lübeck
,
J Ribbat-Idel
2   UKSH - Campus Lübeck, Institut für Pathologie, Lübeck
,
K-L Bruchhage
1   UKSH - Campus Lübeck, Hals-, Nasen- und Ohrenheilkunde, Lübeck
,
S Perner
2   UKSH - Campus Lübeck, Institut für Pathologie, Lübeck
› Author Affiliations
› Further Information
Also available at
 
 

    Introduction TRIM24 is expressed in many cancer entities and often associated with a poor clinical outcome. Head and neck squamous cell carcinoma (HNSCC) is one of the most common cancers world-wide. The treatment of HNSCC is often difficult and associated with severe side-effects while the prognosis is still rather poor.

    Materials & Methods We evaluated the TRIM24 expression in HNSCC tissue by immunohistochemical staining. The results were afterwards correlated with clinical data and clinicopathological features of our well-characterized cohort of 341 patients of which 75 (22 % ) developed al local recurrence (LR).

    Results HNSCC tissues were stained for TRIM24 in the nucleus and in the cytoplasm as well. We could show that TRIM24 was expressed independently of the T Stage und UICC Stage. Primary tumors of patients who developed a local recurrence in the following years, were significantly more often stained positive for TRIM24 than primary tumors which did not develop a local recurrence (p = 0.001). Overall survival (p = 0.002) and progression-free survival (p < 0.001) were significantly worse in patients with positive stained tumors and we could show the independence from other prognostic factors. Furthermore, the time until the development of a recurrence was shortened in patients with TRIM24 positive tumors (p = 0.003).

    Conclusion TRIM24 might be a new prognostic biomarker for survival and the development of a local recurrence in HNSCC patients. It may help to improve the early detection of local recurrences in HNSCC patients who could be included in more frequent follow-up examinations.

    Poster-PDF A-1366.pdf


    #

    Conflict of interest

    Der Erstautor gibt keinen Interessenskonflikt an.

    Address for correspondence

    Idel Christian
    UKSH - Campus Lübeck, Hals-, Nasen- und Ohrenheilkunde
    Lübeck

    Publication History

    Article published online:
    13 May 2021

    © 2021. The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial-License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/).

    Georg Thieme Verlag KG
    Rüdigerstraße 14, 70469 Stuttgart, Germany